| Literature DB >> 27790614 |
Soraya Omardien1, Stanley Brul1, Sebastian A J Zaat2.
Abstract
Antimicrobial peptides (AMPs) have been proposed as a novel class of antimicrobials that could aid the fight against antibiotic resistant bacteria. The mode of action of AMPs as acting on the bacterial cytoplasmic membrane has often been presented as an enigma and there are doubts whether the membrane is the sole target of AMPs. Progress has been made in clarifying the possible targets of these peptides, which is reported in this review with as focus gram-positive vegetative cells and spores. Numerical estimates are discussed to evaluate the possibility that targets, other than the membrane, could play a role in susceptibility to AMPs. Concerns about possible resistance that bacteria might develop to AMPs are addressed. Proteomics, transcriptomics, and other molecular techniques are reviewed in the context of explaining the response of bacteria to the presence of AMPs and to predict what resistance strategies might be. Emergent mechanisms are cell envelope stress responses as well as enzymes able to degrade and/or specifically bind (and thus inactivate) AMPs. Further studies are needed to address the broadness of the AMP resistance and stress responses observed.Entities:
Keywords: Bacillus subtilis; Bacillus subtilis spores; cationic antimicrobial peptides; mode of action; resistance mechanisms
Year: 2016 PMID: 27790614 PMCID: PMC5063857 DOI: 10.3389/fcell.2016.00111
Source DB: PubMed Journal: Front Cell Dev Biol ISSN: 2296-634X
Figure 1The composition of . Image adjusted from Silhavy et al. (2010).
Figure 2The composition of . Image adjusted from McKenney et al. (2013).
Additional information concerning antimicrobial peptides and other antimicrobials mentioned in the texts.
| LL-37 | Human | α-helical | Membrane | Sochacki et al., |
| tPMP | Rabbit blood platelets | α-helical | Membrane | Xiong et al., |
| Thrombocidin | Human blood platelets | α-helical, | Membrane | Krijgsveld et al., |
| Defensin | Mammalian | α-helical, β-sheets | Membrane | Peschel et al., |
| β-defensin 3 (hBD3) | Human | β-sheets | Cell wall | Sass et al., |
| α-defensin neutrophil peptide-1 (HNP1) | Human | α-helical | Cell wall | De Leeuw et al., |
| θ-Defensins | Old world monkeys leukocytes | Cyclic | Membrane | Wilmes et al., |
| Protegrin (PG-1) | Porcine leukocytes | β-sheet | Membrane | Bellm et al., |
| Cecropin A | α-helical | Membrane | Rangarajan et al., | |
| Daptomycin | Cyclic lipopeptide | Membrane | Steenbergen et al., | |
| Indolicin | Extended wedge-like conformation | Membrane | Staubitz et al., | |
| MP196 | Synthetic hexapeptide | Linear peptide | Membrane | Wenzel et al., |
| SMAP-29 | Synthetic peptide derived from cathelicidin | α-helical | Membrane | Skerlavaj et al., |
| Nisin | Lantibiotic | Membrane, cell wall biosynthesis | Bierbaum and Sahl, | |
| Subtilin | Lantibiotic | Membrane, cell wall biosynthesis | Bierbaum and Sahl, | |
| Gallidermin | Lantibiotic | Membrane, cell wall biosynthesis | Kellner et al., | |
| Plectasin | α-helical, β-sheet | Cell wall biosynthesis | Mygind et al., | |
| Mersacidin | Lantibiotic | Cell wall biosynthesis | Brötz et al., | |
| Actagardine or Gardimycin | Lantibiotic | Cell wall biosynthesis | Brötz et al., | |
| Vancomycin | Glycopeptide | Cell wall biosynthesis | Mascher et al., | |
| Bacitracin | Cyclic dodecylpeptide | Cell wall biosynthesis | McDermott et al., | |
| Mundticin KS | Bacteriocin | Unknown (possibly membrane) | Kawamoto et al., | |
| SP1-1 | Synthetic peptide | α-helical | Serine kinase inhibition | Dangel et al., |
Bioestimates of the interaction of LL-37 with .
| Length (l) | 4.7 μm or 2.3 μm | 1.4 μm | ||
| Width (w) | 0.87 μm | 0.55 μm | ||
| Radius (r) | 1/2w | 0.44 μm | 1/2w | 0.28 μm |
| Volume | Vsphere + Vcylinder = 4/3πr3 + πr2(l – w) | 2.6 μm3 or 1.1 μm3 | Vellipsoid = 4/3πlwr | 0.9 μm3 |
| Area | Asphere + Acylinder = 4πr2 + 2πr(l – w) | 12.9 μm3 or 6.3 μm2 | Aellipsoid = 4π((lw)1.6+ (lr)1.6+ (wr)1.6)/3)1/1.6 | 2.4 μm2 |
| Minimal inhibitory concentration (MIC) | 1 μM | 1 μM | ||
| Number of cells | 1 × 106 | 1 × 10m6 | ||
| Volume | 100 μl | 100 μl | ||
| Avogadro's Number is | 6.022 × 1023 per mol | 6.022 × 1023 per mol | ||
| Amount of molecules required to inhibit (N) | 6.0 × 107 molecules per cell | 6.0 × 107 molecules per spore | ||
| Assumed size/radius of LL-37 (4 kDa) | 0.001 μm | 0.001 μm | ||
| Area of LL-37 (sphere) | ALL-37sphere = 4πr2 | 1.5 × 10−5 μm2 | 1.5 × 10−5 μm2 | |
| Area of LL-37 (circle) | ALL-37circle = πr2 | 3.1 × 10−6 μm2 | 3.1 × 10−6 μm2 | |
| Volume of LL-37 (sphere) | VLL-37sphere = 4/3πr3 | 4.2 × 10−9 μm3 | 4.2 × 10−9 μm3 | |
| Amount of LL-37 that covers celll | Ahexagonal = 0.9(AB. subtilis/ALL-37circle) | 3.7 × 106 or 1.8 × 106 | ||
| Amount of LL-37 that fills the cell | Vhexagonal = 0.6(VB. subtilis/VLL-37sphere) | 4.5 × 108 or 1.9 × 108 | ||
| Amount of LL-37 that covers the spore | Ahexagonal = 0.9(AB. subtilis/ALL-37circle) | 6.9 × 105 | ||
| Amount of LL-37 that fills the spore | Vhexagonal = 0.6(VB. subtilis/VLL-37sphere) | 1.7 × 108 | ||
Assuming that the shape of Bacillus subtilis vegetative cell is a cylinder at the center and has two half spheres at the ends and Bacillus subtilis spores is an ellipsoidal shape.
Minimal inhibitory concentration obtained from Barns and Weisshaar (.
Lenght of B. subtilis is 4.7 μm in rich medium and 2.3 μm in minimal medium. Values obtained from .
Values obtained from Leuschner and Lillford (.
Assuming hexagonal close packing of circles or spheres. A value of 0.9 is used to compensate for hexagonal close packing of circles and a value of 0.74 is used for spheres.
Bionumbers of the .
| Thickness | 33.8 nm | NA | |
| Teichoic acids | 54% | SVC | Graham and Beveridge, |
| Peptidoglycan | 46% | SVC | |
| Protein | 62% | SVC | Bishop et al., |
| RNA | 22% | SVC | |
| Phospholipids | 16% | SVC | |
| Cardiolipin | 10% of phospholipid | SVC | López et al., |
| Phosphatidylglycerol | 25% of phospholipid | SVC | |
| Phosphatidylethanolamine | 50% of phospholipid | SVC | |
| Lysyl-phosphatidylglycerol | 15% of phospholipid | SVC | |
| DNA | 4215 kb | SVC | Logan and De Vos, |
| RNA | NA | SVC | |
| Ribosomes | NA | SVC | |
| Protein | NA | SVC | |
| Mobile genetic elements | NA | SVC | |
| Outer coat layer | 40–90 nm | Henriques and Moran, | |
| Inner coat layer | 20–30 nm | ||
| Protein | 10% | Munoz et al., | |
| Outer membrane | NA | ||
| Peptidoglycan | NA | ||
Values obtained from .
Similar as vegetative cells (SVC) (Popham, .
Not available (NA).
Figure 3The partial membrane lipid synthesis pathway of . The precursor phosphatidic acid (PA), a common precursor for the membrane phospholipids, is dephosphorylated to diacylglycerol which is modified by UgtP through transferring one or two glucose molecules from UDP-glucose resulting in glycolipid (GL). Phosphotidylglycerol (PG) is converted to lysyl-PG when a lysyl group from lysyl-tRNALys is transferred to PG by MprF. PG is also converted to cardiolipin by combining two PG molecules. Image adjusted from Salzberg and Helmann (2008).